Ovid Therapeutics Stock Forecast, Price & News

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 0.0% and is now trading at $2.68.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ovid Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Ovid Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Thursday, November, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.07.
View Ovid Therapeutics' earnings history.

9 Wall Street analysts have issued 1-year target prices for Ovid Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they anticipate Ovid Therapeutics' share price to reach $12.57 in the next year. This suggests a possible upside of 369.1% from the stock's current price.
View analysts' price targets for Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,050,000 shares, an increase of 15.1% from the October 31st total of 2,650,000 shares. Based on an average daily volume of 949,200 shares, the days-to-cover ratio is presently 3.2 days. Approximately 8.5% of the company's shares are sold short.
View Ovid Therapeutics' Short Interest.

Some companies that are related to Ovid Therapeutics include Akouos (AKUS), Collegium Pharmaceutical (COLL), Emisphere Technologies (EMIS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), BioSpecifics Technologies (BSTC), Avid Bioservices (CDMO), Basilea Pharmaceutica (BPMUF), Odonate Therapeutics (ODT), Eagle Pharmaceuticals (EGRX), IVERIC bio (ISEE), Chinook Therapeutics (KDNY), Mirum Pharmaceuticals (MIRM), ZIOPHARM Oncology (ZIOP) and RAPT Therapeutics (RAPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.83%), Vivo Capital LLC (2.19%), Sofinnova Investments Inc. (1.92%), State Street Corp (1.27%), AXA S.A. (1.04%) and Wells Fargo & Company MN (0.94%). Company insiders that own Ovid Therapeutics stock include Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA S.A., Platinum Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, State Street Corp, JPMorgan Chase & Co., and Virtus ETF Advisers LLC.
View insider buying and selling activity for Ovid Therapeutics.

OVID stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Sofinnova Investments Inc., Squarepoint Ops LLC, First Trust Advisors LP, Blair William & Co. IL, GSA Capital Partners LLP, OLD Mission Capital LLC, and AQR Capital Management LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $2.68.

Ovid Therapeutics has a market capitalization of $170.01 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 60 workers across the globe.

The official website for Ovid Therapeutics is www.ovidrx.com.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]